Acanthamoeba Keratitis Market

DelveInsight’s “Acanthamoeba keratitis – Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Acanthamoeba keratitis, historical and forecasted epidemiology as well as the Acanthamoeba keratitis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Acanthamoeba keratitis market report provides current treatment practices, emerging drugs, Acanthamoeba keratitis market share of individual therapies, and current and forecasted Acanthamoeba keratitis market size from 2019 to 2032, segmented by seven major markets. The report also covers current Acanthamoeba keratitis treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study period: 2019–2032

Acanthamoeba keratitis Understanding and Treatment Algorithm

The DelveInsight’s Acanthamoeba keratitis market report gives a thorough understanding of Acanthamoeba keratitis by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

Acanthamoeba keratitis is a rare but serious infection of the eye that can result in permanent visual impairment or blindness. This infection is caused by a microscopic, free-living amoeba called Acanthamoeba. Two of the eight known species of Acanthamoeba, A. castellanii and A. polyphaga, are responsible for most infections. The organism infects the transparent outer covering of the eye called the cornea. The protozoan is ubiquitous and can be found in water bodies (for example, lakes and oceans), soil, air, cooling towers, heating, ventilating, air conditioning (HVAC) systems, and sewage systems.

The condition is commonly misidentified as one of the more common fungal or viral forms of keratitis, especially ocular herpes, often delaying diagnosis. Corneal trauma, ocular surgery, contact lens use, and low levels of anti-acanthamoeba IgA in tears are all risk factors for the development of Acanthamoeba keratitis. When the epithelial layer of the cornea is damaged, it is left susceptible to infection by fungi, bacteria, or protozoa. Prior to the widespread use of contact lenses, corneal abrasions and exposure to contaminated water or soil were the most distinguishable risk factors for Acanthamoeba keratitis.

Contact lenses can help Acanthamoeba reach the cornea and exacerbate the progression of the disease. The lenses serve as a physical route of passage from a contaminated source directly to the cornea. Lenses, especially when worn improperly or for longer than recommended, erode the corneal epithelium, allowing microbial entry. Sufferers of Acanthamoeba keratitis typically complain of redness, pain, decreased visual acuity, and sensitivity to light. The most distinctive clinical feature of Acanthamoeba keratitis is a pronounced ring-like stromal infiltrate, believed to be composed of inflammatory cells. Signs of scleritis, corneal inflammation, and conjunctival hyperemia begin to appear as the disease progresses. If left untreated, Acanthamoeba can spread back into the retina and cause serious chorioretinitis, and patients are often reduced to a visual acuity of hand movement or blindness in these later stages.

Acanthamoeba keratitis diagnosis

Proper early-stage diagnosis is essential, though difficult as typical Acanthamoeba keratitis symptoms are difficult to associate. In vivo confocal microscopy along with polymerase-chain-reaction (PCR), histopathological examination, and microbiological culture is used to confirm the diagnosis once clinical signs are recognized. However, misidentification often delays diagnosis and proper treatments which makes progression rapid.

Acanthamoeba keratitis treatment

Acanthamoeba keratitis is difficult to treat, but effective management can keep a patient from going blind. Medical treatment is still evolving and various combinations of diamidines, biguanides, antibiotics, and antifungals are often used off-label. Oral miltefosine is also used in refractory cases of Acanthamoeba keratitis. In therapy-resistant cases, surgical treatment options are applied.

Disease resolution typically requires prolonged therapy which is costly and laborious and may be complicated by stromal scarring and reoccurrence. With the disease on the rise, adequate treatment is a significant unmet clinical need for this parasitic corneal infection, as no treatment is currently licensed for Acanthamoeba keratitis in any country.

Acanthamoeba keratitis Epidemiology

The Acanthamoeba keratitis epidemiology section provides insights into the historical and current Acanthamoeba keratitis patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Acanthamoeba keratitis report also provides the diagnosed patient pool, their trends, and assumptions undertaken.

Key findings

According to the US Centers for Disease Control and Prevention (CDC), the majority of those who are affected by AK wear contact lenses. An estimated 85% of cases in the US involve people who wear contact lenses. Although further research is needed, the incidence of the illness in the United States has been conservatively estimated at one to two cases per million contact lens users.

The Acanthamoeba keratitis epidemiology covered in the report provides historical as well as forecasted Acanthamoeba keratitis epidemiology [segmented as the Total number of cases using contact lenses, Total Incident cases of Acanthamoeba keratitis, Genotype-specific cases of Acanthamoeba keratitis, and Total treated cases of Acanthamoeba keratitis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

Country-wise Acanthamoeba keratitis Epidemiology

The epidemiology segment also provides the Acanthamoeba keratitis epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Acanthamoeba keratitis Drug Chapters

The drug chapter segment of the Acanthamoeba keratitis report encloses a detailed analysis of Acanthamoeba keratitis marketed drugs and late-stage (Phase III and Phase II) Acanthamoeba keratitis pipeline drugs. It also helps understand the Acanthamoeba keratitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Acanthamoeba keratitis drugs

The report details the emerging Acanthamoeba keratitis therapies under the late and mid-stage of development for Acanthamoeba keratitis treatment.

Acanthamoeba keratitis Market Outlook

The Acanthamoeba keratitis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Acanthamoeba keratitis market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

This segment gives a thorough detail of the Acanthamoeba keratitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Acanthamoeba keratitis market in the 7MM is expected to witness a major change in the study period 2019–2032.

Key findings

This section includes a glimpse of the Acanthamoeba keratitis market in the 7MM.

The United States: Acanthamoeba keratitis Market Outlook

This section provides the total Acanthamoeba keratitis market size and market size by therapies in the United States.

EU4 and the UK Countries: Acanthamoeba keratitis Market Outlook

The total Acanthamoeba keratitis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan: Acanthamoeba keratitis Market Outlook

The total Acanthamoeba keratitis market size and market size by therapies in Japan are also mentioned.

Acanthamoeba keratitis Drug Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Acanthamoeba keratitis market or expected to get launched in the market during the study period 2019–2032. The analysis covers the Acanthamoeba keratitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

This will help in understanding the Acanthamoeba keratitis drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Acanthamoeba keratitis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Acanthamoeba keratitis’s key players involved in developing targeted therapeutics.

Acanthamoeba keratitis market clinical trial development activities

The report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information on Acanthamoeba keratitis's emerging therapies.

Acanthamoeba keratitis Reimbursement Scenario

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL Views

To keep up with current epidemiology and market trends, we take KOLs and SMEs' opinions working in the Acanthamoeba keratitis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns along with Acanthamoeba keratitis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the Acanthamoeba keratitis market by using various competitive intelligence tools that include – SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• Descriptive overview of Acanthamoeba keratitis, disease overview, patient journeys, treatment algorithms, diagnosis, and currently available therapies
• Comprehensive insight into the Acanthamoeba keratitis epidemiology and forecasts in the 7MM
• An all-inclusive account of both the current and emerging therapies for Acanthamoeba keratitis, along with the assessment of new therapies, expected to have an impact on the current treatment landscape
• Exhaustive analysis of the Acanthamoeba keratitis market; historical and forecasted covering drug outreach in the 7MM
• Detailed patient-based market forecasting determines the trends shaping and driving the global Acanthamoeba keratitis market

Report Highlights

• In the coming years, the Acanthamoeba keratitis market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Acanthamoeba keratitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing Acanthamoeba keratitis therapies. The launch of emerging therapies will significantly impact the Acanthamoeba keratitis market
• A better understanding of Acanthamoeba keratitis pathogenesis will also contribute to the development of novel therapeutics for Acanthamoeba keratitis
• Our in-depth analysis of the Acanthamoeba keratitis pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Acanthamoeba keratitis Report Insights

• Patient-Based Market Forecasting
• Therapeutic approaches
• Acanthamoeba keratitis pipeline analysis
• Acanthamoeba keratitis market size and trends
• Acanthamoeba keratitis market opportunities
• Impact of upcoming therapies

Acanthamoeba keratitis Report Key Strengths

• 11 years forecast
• 7MM Coverage
• Acanthamoeba keratitis epidemiology segmentation
• Key cross competition
• KOL views
• Acanthamoeba keratitis drugs uptake

Acanthamoeba keratitis Report Assessment

• Current treatment practices
• Unmet needs
• Acanthamoeba keratitis pipeline product profiles
• Acanthamoeba keratitis market attractiveness

Key Questions

Acanthamoeba keratitis market insights:

• What would be the Acanthamoeba keratitis market growth till 2032, and what will be the resultant market size in 2032?
• What was the Acanthamoeba keratitis drug class share (in percentage) distribution in 2019, and how would it look in 2032?
• What would be the Acanthamoeba keratitis total market size and market size by therapies across the 7MM during the forecast period (2022–2032)?
• What are the key findings of the market across 7MM, and which country will have the largest Acanthamoeba keratitis market size during the forecast period (2022–2032)?
• How would the unmet needs affect the Acanthamoeba keratitis market dynamics and subsequent analysis of the associated trends?

Acanthamoeba keratitis Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Acanthamoeba keratitis?
• What is the historical and forecasted Acanthamoeba keratitis patient pool in the 7MM, and where can one observe the highest patient population and growth opportunities?
• What are the key factors driving the epidemiology trends for seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current treatment guidelines and treatment options, in addition to approved therapies for Acanthamoeba keratitis in the US, Europe, and Japan?
• What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to Acanthamoeba keratitis therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acanthamoeba keratitis and its status, along with the challenges faced?

Reasons to Buy

• The patient-based market forecast analysis will help in developing business strategies by understanding trends shaping and driving the Acanthamoeba keratitis market
• Organize sales and marketing efforts by identifying the best opportunities for Acanthamoeba keratitis in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan
• Identification of strong upcoming players in the market that will help devise strategies that will help in getting ahead of competitors